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Abstract
Background: Human bocavirus (HBoV) is a newly discovered parvovirus and increasing evidences are available to support
its role as an etiologic agent in lower respiratory tract infection (LRTI). The objective of this study is to assess the impact of
HBoV viral load on clinical characteristics in children who were HBoV positive and suffered severe LRTI.
Methods: Lower respiratory tract aspirates from 186 hospitalized children with severe LRTI were obtained by bronchoscopy.
HBoVs were detected by real-time PCR and other 10 infectious agents were examined using PCR and/or direct fluorescent
assay.
Results: Thirty-one patients (24.6%) were tested positive for HBoV in the respiratory tract aspirates. Fifteen samples had a
high viral load (.10
4 copies/mL) and the other sixteen samples had a low viral load (,10
4 copies/mL). The duration of
presented wheezing and hospitalization was longer in children with high viral load of HBoV than that in children with low
viral load. The days of wheezing showed a correlation with viral load of HBoV.
Conclusion: We confirmed that HBoV was frequently detected in patients with severe LRTI. Wheezing was one of the most
common symptoms presented by patients with positive HBoV. A high HBoV viral load could be an etiologic agent for LRTI,
which led to more severe lower respiratory tract symptom, longer duration of wheezing and hospitalization.
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Introduction
Human bocavirus (HBoV) is a newly discovered parvovirus that
was first identified in Sweden from pooled nasopharyngeal aspirate
specimens by large-scale molecular virus screening [1]. Increasing
evidences are emerging to support its role as an etiologic agent in
lower respiratory tract infection (LRTI) [2,3,4,5].
HBoV is frequently detected in patients with acute respiratory
tract infection [6,7,8], including in those who are having
wheezing, croup, cough, rhinorrhea and fever [2,9]. A number
of epidemiological and clinical investigations have been conducted
to assess HBoV- related illness; its clinical features have been
reported, which resembled those of respiratory syncytial virus
(RSV) and human metapneumovirus (hMPV) infections [10]. The
most frequent clinical diagnoses associated with respiratory HBoV
are general upper respiratory tract infections, bronchiolitis,
pneumonia, bronchitis and asthma exacerbation [2]. Nevertheless,
few data are available related to physical characteristics and
clinical severity for children with HBoV-positive LRTIs [7].
In this study we aimed to assess the relationship between the
HBoV viral load in respiratory tract and clinical characteristics.
To achieve this goal, we conducted the study to compare the
clinical characteristics, cytokine/chemokine data in respiratory
tract aspirates between two groups of children who had HBoV
infection with either high or low viral load.
Methods
Research subjects and respiratory tract aspirates
collection
The study population was hospitalized (in the Department of
Respiratory Medicine, Children’s Hospital, Chongqing Medical
University) and underwent bronchoscopy. The study was
conducted from April 2006 to March 2009. A total of 186
sequential respiratory tract aspirate samples were collected.
Informed consent was properly obtained from each patient’s
guardians. The informed consent was written and signed by
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34353guardian before bronchoscopy. This study was approved by the
Ethical Committee of Chongqing Medical University.
On admission, the medical history and physical examination of
the children were properly obtained and recorded systematically.
In this study, we defined LRTI as having following characteristics:
presence of wheezing, crackling rales, dyspnea, and/or obstruction
of the airways, with or without fever, and presence of upper airway
symptoms characterized by rhinorrhea and bronchitic cough. All
patients with suspected LRTI underwent chest radiography.
Pneumonia was defined as the presence of focal infiltration or
lung consolidation presented in chest radiography.
Respiratory tract aspirates preparation
After respiratory tract aspirates were collected, the aspirates
were gently mixed with Pasteur pipette and revolve for a while
until they were evenly mixed, then 0.5 ml of each aspirate was
transferred to another tube for cytokine analysis. Four volumes of
0.1% dithiothreitol was added to the 0.5 ml respiratory tract
aspirates, then gently mixed with Pasteur pipette, votexed
15 seconds and shook 15 minutes on bench rocker. The
suspension was subsequently filtered through 48 mm nylon gauze
to remove mucus and debris without removing any cells, and then
it was centrifuged at 1500 rpm for 10 minutes. The cell free
supernatant was stored at 280uC for cytokine assay. The cell
pellet was resuspended for viral antigen detection using direct
fluorescent assay inmediately. The rest of aspirates were stored at
280uC before virus detection by polymerase chain reaction (PCR)
assay.
Real-time PCR for HBoV
Nucleic acids were extracted from 200 mL of the aspirates using
the QIAamp DNA mini kit (Qiagen, USA) and the samples were
eluted in 200 mL of RNasefree water. The PCR assay targeted the
NP-1 gene of HBoV. The 20-mL amplification reaction contained
5 mL of sample DNA, 10 mL of TaqMan universal PCR master
mix (PE Applied Biosystems), 0.1 mL of bovine serum albumin
(20 mg/mL), 300 nmol/L each primer (Boca-forward, GGA AGA
GAC ACT GGC AGA CAA; and Boca-reverse, GGG TGT TCC
TGA TGA TAT GAG C), and 150 nmol/L Boca probe (FAM-
CTG CGG CTC CTG CTC CTG TGA T-TAMRA). Ampli-
fication was performed on a LightCycler 1.2 instrument (Roche)
with the following settings: 95uC for 10 min, 50 cycles of 95uC for
30 sec, and 60uC for 1 min. For standardizing the quantification,
a plasmid (NPSC3.1) containing the HBoV NP-1 gene was used in
serial dilutions covering a range of 6 logs. The criteria for a
positive reaction were defined as the cycle threshold ,40 cycles
and fluorescence count .0.5. The minimum genome viral load
that would allow reproducible quantification was 10 copies per
reaction, which corresponds to 500 copies/mL of respiratory tract
aspirates. The analyses were performed at a diagnostic laboratory,
where rigorous measures were implemented to prevent contam-
ination.
Means of diagnosis for other viruses
Viral antigens were analyzed for adenovirus (ADV), influenza
virus A and B (Flu-A and B), parainfluenza virus 1, 2 and 3 (PIV
1–3) and RSV using direct fluorescent assay (D3 direct fluorescent
assay RESPIRATORY VIRUSES SCREENING & ID KIT,
DIAGNOSTIC HYBRIDS, Germany); PCR was used for the
detection of ADV; reverse transcription-PCR was used for the
detection of rhinovirus (RV), RSV, human coronaviruses OC43
(HCoV), Flu-A and B, PIV 1–3 and hMPV. DNA was extracted
from 200 mL of the aspirates using the QIAamp DNA mini kit
(Qiagen, USA) and was eluted in 200 mL AE buffer. RNA was
extracted from 140 mL of the aspirates using the QIAamp Virus
RNA Mini kit (Qiagen, USA), and samples were eluted in 60 mL
of RNase-free water. Reverse transcription of 0.5 mg of each RNA
was performed in a final reaction of 10 mL that contained 25-pmol
Oligo dT primer, 50 pmol random 6-mers, 56PrimeScript Buffer
and 0.5 mL PrimeScript RT Enzyme Mix (TaKaRa, Japan).
Amplification was performed with a Bio-Rad thermal cycler, using
commercially available master mixes (Promega, USA) and
standard protocols. All PCR assays were performed using 2 mlo f
cDNA/DNA and 1 mM of each primer. In addition, the primer
sequences, PCR protocols and other viral detection methods are
described elsewhere [11]. The unclassified RVs were identified as
RVs. A patient was considered to be positive for the virus only if
having at least one positive result from the two methods.
Bacterial isolation
Bacterial/yeast diagnostic samples were processed immediately
in a qualitative and semi-quantitative ways using standard
microbiological methods [12,13]. For all samples, macroscopically
distinct colonies were isolated in pure culture and standard
methods for identification, typing, and sensitivity patterns were
used.
Cytokine/chemokine analysis
By following the instructions, respiratory tract aspirates were
tested for interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-
10 (IL-10) by enzyme linked immunosorbent assay (ELISA) (BD
Pharmingen, USA). Each sample was measured in duplicate using
VARIOSKAN FLASH (Thermo) by following manufacturer’s
instructions. The concentration of each cytokine was determined
by interpolation from the corresponding standard curve. When the
values were below the detection threshold, the minimum
detectable level was assigned.
Statistical analysis
Data on the descriptive characteristics of the patients were
analyzed by x2, Fisher’s exact test. Non-parametric tests and
median values were used for those variables, because they were not
normally distributed, such as cytokine/chemokine concentrations.
Correlations were made with Spearman’s two-tailed rank
correlation in addition to Pearson’s linear regression two-tailed
analysis. For all outcomes and relations between variables,
differences between groups were considered statistically significant
at P,0.05. SPSS (version 17.0) was used for all analysis.
Results
Frequency and distribution of HBoV detection
The patient demographics and clinical information were
summarized in Table 1. HBoV DNA was detected by PCR in
31 out of 186 patient’s samples (24.6%). All samples were also
tested for the other respiratory viruses, including RSV (32.8%),
RV (22.4%), hMPV (2.4%), FLU (20%), HPIV (44%), HCoV
(1.6%) and ADV (4.8%). Among all 31 HBoV-positive samples, 12
samples (38.71%) were only being detected for HBoV, while in
other 19 samples there were one more virus were being detected
besides HBoV. It was noticed that the most common coinfection
viruses with HBoV were RSV (in 4 children), RV (in 3 children)
and ADV (in 2 children).
HBoV DNA was detected all year round, seasonal distribution
of HBoV was noted during October through March. The period
from January to March was the seasonal peak that overlapped
with the period of RSV peak, which may explained that why RSV
was being the most common co-infection virus with HBoV.
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For the purpose of the analysis, the patients were divided into
two groups: those with HBoV infection and those without HBoV
infection. The most frequent respiratory symptoms/signs (present
in .50%) seen in HBoV-positive patients were cough and
wheezing. Significantly high frequency of wheezing (90.322% vs.
72.903%, p=0.04) and dyspnea (41.935% vs. 13.548%, p=0.001)
were noted in 31 HBoV-positive patients, in comparison with 155
HBoV-negative patients. (Table 2). Furthermore a significant
difference was noted in the length of hospital stay between HBoV-
positive and HBoV-negative patients (Table 2). In general, the
clinical findings were more severe in patients with HBoV infection.
Clinical characteristics of patients who had positive HBoV
with or without co-infection with other viruses or
bacteria
The clinical characteristics of children who had detectable
HBoV with or without co-infection with other viruses or bacteria
were shown in Table 3 and Table 4. In table 3, the two groups
were similar in all clinical manifestations, duration of hospitaliza-
tion and wheezing.
Among all HBoV-positive samples, 67.74% were also positive
for bacteria. No significant difference was found in whether it was
associated with bacteria or not (Table 4). Therefore, our findings
did not support the existence of significant interactions between
HBoV and other respiratory viruses or bacteria. This finding
clearly suggested the pathogenic potential of HBoV in young
children with LRTI.
Quantitative analysis of HBoV DNA in the respiratory
aspirates
Absolute quantification of DNA by qPCR revealed that the
HBoV viral load in HBoV-positive patients varied very broadly,
ranged from ,500 to 1610
9 copies per mL of sample material,
with median value of 9912 (figure 1). The median viral load which
was found in patients with sole HBoV infection was not higher
than those who had co-infection with other respiratory viruses
(p=0.2517). A recent review suggested if serum samples were not
available for PCR, and then the probable next best option was the
quantitative PCR with a cutoff of .10
4 copies/mL of respiratory
tract secretions [14]. Several previous studies reported that
increased serum HBoV IgM and IgG had been found in most
of patients who had high HBoV load (.10
4 copies/mL) in
respiratory tract secretions, which was associated with respiratory
symptoms [2,15,16]. Therefore the HBoV-positive samples were
divided into 2 non-overlapping populations: one group of 15
samples with a high viral load (.10
4 copies/mL) and one group of
16 samples with a low viral load (,10
4 copies/mL).
Clinical characteristics of patients with high HBoV viral
load
High HBoV viral load was detected in 15 patients. The
comparisons of demographics and clinical data among patients
who were shedding high HBoV (.10
4 copies/mL of respiratory
tract aspirates) and those who were shedding low HBoV were
shown in table 5. In HBoV-positive patients, the distributions of
age and gender were not different between the two groups. Almost
all of HBoV-positive patients presented cough and wheezing. Non-
specific lower respiratory tract symptoms, such as fever and
rhinorrhea, had no significant correlation with HBoV viral load.
However, the symptoms observed in patients with serious LRTIs,
like tachypnea, dyspnea and cyanosis, were presented more
frequently in children with high HBoV viral loads, and the mean
Table 1. Demographic and clinical characteristics of patients
(n=186).
Clinical data n (%)
Mean age (Months 6 SEM) 23.4162.56
Male 112 (60.22)
Median hospital length of stay (median, IQR) (days) 9 (2–31)
Chest radiograph
Any abnormality 150 (80.65)
Multifocal infiltrates or consolidation 16 (10.67)
Diffuse infiltrates 65 (43.33)
Hyperinflation 17 (6.00)
Atelectasis 21 (14)
Interstitial abnormality 39 (26.00)
Clinical diagnosis
Bronchial pneumonia 15 (8.06)
Interstitial lung diseases 109 (58.60)
Asthma 39 (20.97)
Bronchiolitis obliterans 6 (3.23)
Others 17 (9.14)
doi:10.1371/journal.pone.0034353.t001
Table 2. Clinical features of HBoV-positive patients.
Clinical data HBoV-positive samples (n=31) HBoV-negative samples (n=155) P
Cough 31 (100%) 155 (100%) 1
Wheezing 28 (90.32%) 113 (72.90%) 0.040*
Fever 13 (41.94%) 51 (32.90%) 0.408
Tachypnea 20 (64.52%) 79 (50.97%) 0.237
Dyspnea 13 (41.94%) 21 (13.55%) 0.001*
Rhinorrhea 6 (19.36%) 19 (12.26%) 0.384
Cyanosis 12 (38.71%) 61 (39.36%) 1
Duration of hospitalization (days) (mean6SEM) 12.1061.101 9.90360.456 0.0292**
*Calculated using the fisher’s exact test. P,0.05 was considered to be significantly different between each other.
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t002
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which was significantly longer than in children with low HBoV
viral load.
Cytokine/chemokine concentration
Cytokine/chemokine concentrations of the respiratory tract
aspirates from patients with HBoV infection were shown in
Table 6. In patients with high HBoV viral load, IL-8 level was
found higher than those who had low HBoV viral load. The IL-6
and IL-10 levels were very similar between the two groups.
In order to identify whether the potential co-infections would
influence the cytokine production and the biological significance of
IL-8, IL-6 and IL-10, we compared IL-8, IL-6 and IL-10
productions between patients with only HBoV detection, and
patients with HBoV and other viruses or bacteria detection, no
significant differences were found (table 7 and table 8).
Association of HBoV in respiratory tract aspirates,
duration of hospitalization and days of wheezing
Longer duration of hospitalization and days of wheezing were
found among children with high HBoV loads (table 5). Then we
looked atthe correlation between viralloads and duration ofhospital
stay and days of wheezing, we searched for additional evidence of
etiology by studying whether the viral load of HBoV was unrelated
or correlated to the days of hospitalization and presented wheezing.
And we found that the days of wheezing showed a direct correlation
with viral load (Correlation coefficient=0.538. P=0.003) (Figure 2).
Discussion
In this study, 24.6% of patients with serious lower respiratory
tract illness were detected having HBoV in their respiratory tract
aspirates. We confirmed that HBoV was frequently detected in
children with severe LRTIs. Wheezing was one of the most
common symptoms presented by HBoV-positive patient. HBoV at
a high load could be an etiologic agent for LRTIs, which led to
more severe lower respiratory tract symptom, longer hospitaliza-
tion, and longer duration of wheezing.
HBoVs have been detected worldwide, low HBoV viral load
was usually more frequently detected than high HBoV viral load
in children [17,18,19], its role as a pathogen in respiratory tract
was often questioned. However, HBoV at a high load were clearly
suggested for being an etiologic agent for respiratory tract disease
[2]. In our study, fifteen out of thirty-one HBoV-positive patients
who had high HBoV viral loads, presented acute primary
infection. Symptoms, duration of hospitalization were compared
among patients who had LRTI with or without HBoV infection.
Table 3. Clinical characteristic of children who had HBoV detection with or without detection of other viruses.
Clinical data HBoV sole (n=12) HBoV coinfection (n=19) P
Cough 12 (100%) 19 (100%) 1.000
Wheezing 12 (100%) 17 (89.47%) 0.510
Fever 5 (41.67%) 9 (47.37%) 1.000
Tachypnea 9 (75.00%) 11 (57.89%) 0.452
Dyspnea 9 (41.94%) 14 (13.55%) 1.000
Rhinorrhea 2 (16.67%) 4 (21.05%) 1.000
Cyanosis 11 (38.71%) 16 (39.36%) 1.000
Duration of hospitalization (days) (mean6SEM) 11.9261.852 12.2161.403 0.855
Duration of presented wheezing (days) (mean6SEM) 23.3362.23 21.4262.72 0.9515
*Calculated using the fisher’s exact test. P,0.05 was considered to be significantly different between each other.
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t003
Table 4. Clinical characteristic of children who had HBoV detection with or without detection of bacteria.
Clinical data HBoV without bacteria detection (n=10)
HBoV with bacteria detection
(n=21) P
Cough 10 (100%) 21 (100%) 1.000
Wheezing 8 (80%) 20 (95.24%) 0.237
Fever 5 (50%) 8 (38.10%) 0.701
Tachypnea 6 (60%) 14 (66.67%) 1.000
Dyspnea 3 (30%) 5 (23.81%) 1.000
Rhinorrhea 3 (30%) 4 (19.04%) 0.681
Cyanosis 4 (40%) 8 (38.10%) 1.000
Duration of hospitalization (days) (mean6SEM) 10.0061.033 13.1061.516 0.236
Duration of presented wheezing (days) (mean6SEM) 18.6064.47 23.8661.714 0.410
*Calculated using the fisher’s exact test. P,0.05 was considered to be significantly different between each other.
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t004
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longer hospital stay. These findings suggested that HBoV was one
of the common pathogens for children with serious LRTIs.
Although, increasing number of studies suggested the pathogenic
potential of HBoV in young children with respiratory tract
infections, however HBoVs were frequently detected in asymptom-
atic children’s respiratory tract secretions, which may raise some
justifiable concerns for etiology [1,20–29]. The variation of HBoV
detection in these studies was likely attributable to multiple factors,
suchas patient’s age, season, geographic location, primer sensitivity,
laboratory technique, true variation in incidence of HBoV, and
methods used in sample collection. Some studies suggested that
persistent virus shedding was therefore being a reasonable
explanation for the high occurrence of HBoV in healthy subjects
[20]. Moreover failure for follow-up on HBoV-positive asymptom-
atic children also led to high occurrence of HBoV detection in
asymptomaticchildren.Recently,aninvitrostudyofHBoVinfection
in pseudostratified epithelial cells was established to confirm the
virus uptake,transcription, andreplication [30]. This studysupports
the concept that HBoV is a respiratory pathogen.
In agreement with previous studies, co-infection with other
pathogens was common in HBoV-positive patients in our study,
but no significant differences were found in term of frequencies of
specific respiratory symptoms, duration of hospitalization, wheez-
ing and the cytokine production in patients with HBoV infection
only and patients with co-infection with other viruses or bacteria.
Clearly, our results indicated potential co-infections will not
influence clinical outcome of HBoV infection in respiratory tract.
This finding strongly suggested the pathogenic potential of HBoV
in young children with LRTI.
Because virus co-infection would not increase illness duration or
severity in virus-induced respiratory disease in our study or the
others [20,31–34]. Therefore the more severe lower respiratory
tract symptom presented in high HBoV viral load patients may
solely depend on HBoV viral load. In our study, HBoV viral load
did not show significant influence on the presentations of upper
respiratory tract infection symptoms, such as cough, rhinorrhea,
however high HBoV viral load led to more severe lower
respiratory tract symptoms and longer hospitalization. It was also
indicated in vitro studies that viral infection resulted in the high IL-
8 level and other pro-inflammatory molecules; these cytokines
were likely to bring in additional neutrophils and also to cause
hyper-responsiveness in bronchus, which could contribute to the
severity of both upper and lower respiratory symptoms during the
viral infection. In our study, the IL-8 level was significantly higher
in patients with high HBoV viral loads that those who with low
viral load. Overall, our findings indicated that the high HBoV viral
loads played an important role in the severity of LRTIs, the
symptoms and the duration of hospital stay.
No previous studies showed the distinctive clinical signs that
help to differentiate HBoV-positive infections from other viral
infections [35,36]. In our study, main clinical symptoms in HBoV-
positive patients included cough (100%), wheezing (90.32%), and
fever (41.94%). Although the existence of HBoV was not directly
associated with the illness, some studies showed wheezing was the
main manifestation of HBoV infection [2,4,37–39]. Our data was
Figure 1. Distribution of human bocavirus (HBoV) viral loads.
Thirty one respiratory aspirate samples were tested positive for HBoV.
Each sample is represented by a single dot. Viral loads in the
nasopharyngeal aspirates ranged from ,500 to 1610
9 copies per mL
of sample material. The dotted line indicates the cutoff between the high
(.10
4 copies/mL) and low (,10
4 copies/mL) HBoV viral load groups.
doi:10.1371/journal.pone.0034353.g001
Table 5. Clinical data of patients with different HBoV viral load.
Clinical data HBoV-positive patients, viral load P
,10
4 copies/mL (n=16) $10
4 copies/mL (n=15)
Masculine gender 10(62.5%) 10(66.7%) 1
Age (median of months) 6.5 10 0.178
Cough 16(100%) 15(100%) 1
Wheezing 14(87.5%) 14(93.33%) 1
Fever 8(50%) 5(33.3%) 0.473
Tachypnea 7(43.75%) 13(86.67%) 0.023*
Dyspnea 3(18.75%) 10(66.7) 0.011*
Rhinorrhea 4(25%) 2(13.33%) 0.654
Cyanosis 3(18.75%) 9(60%) 0.029
Duration of hospitalization (days) (mean6SEM) 8.7560.91 14.6761.93 0.0082**
Duration of presented wheezing (days) (mean6SEM) 26.43+2.27 20.47+2.115 0.0274**
*Calculated using the fisher’s exact test. P,0.05 was considered to be significantly different between each other.
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t005
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that wheezing was one of the most common symptoms presented
in HBoV- positive patients. We also investigated the relationship
between HBoV viral load and duration of wheezing, we found that
the days of wheezing correlated with viral load. Emily et al
documented that persistent HBoV shedding, may increase the
duration of respiratory symptoms [6]. This report may explain the
link between HBoV load and persistent wheezing.
Because our study is a comprehensive clinical observation on
HBoV- positive patients with severe LRTIs, failure of follow-up was
one of the limitations to our study, which may led to the loss of some
important data, suchasthe impactof persistentviral shedding on the
infection prognosis during the acute viral infection. It is also
important to assess theasthmadevelopmentinthesecases ifpossible.
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Table 6. Cytokine/chemokine concentrations of respiratory tract aspirates in children with different HBoV viral load.
Cytokine/chemokine (pg/mL) ,10
4 copies/mL (n=16) $10
4 copies/mL (n=15) P
Interleukin-8 19896435.6 405.46162.1 0.0015**
Interleukin-6 21.77616.79 49.71627.7 0.6597
Interleukin-10 36.23610.92 42.6468.416 0.7685
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t006
Table 7. Cytokine/chemokine concentrations of respiratory tract aspirates in children who had HBoV detection with or without
detection of other viruses.
Cytokine/chemokine (pg/mL) HBoV sole (n=12) HBoV coinfection (n=19) P
Interleukin-8 18046711.3 25996738.3 0.488
Interleukin-6 30.3065.988 49.81613.94 0.533
Interleukin-10 40.35613.21 53.5967.858 0.7371
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t007
Table 8. Cytokine/chemokine concentrations of respiratory tract aspirates in children who had HBoV detection with or without
detection of bacteria.
Cytokine/chemokine (pg/mL) HBoV without bacteria detection (n=10) HBoV with bacteria detection (n=21) P
Interleukin-8 241361110 22196611.8 0.977
Interleukin-6 31.5068.051 46.03611.76 0.687
Interleukin-10 52.63614.90 47.4567.389 0.941
**Calculated using the Mann-Whitney U test. P,0.05 was considered to be significantly different between each other.
doi:10.1371/journal.pone.0034353.t008
Figure 2. Correlation between HBoV viral load and days of
wheezing. HBoV viral load was correlated to the days of presented
wheezing. Correlations were made with Spearman’s two-tailed rank
correlation in addition to Pearson’s linear regression two-tailed analysis.
Correlation coefficient=0.538, P=0.003.
doi:10.1371/journal.pone.0034353.g002
Human Bocavirus and Wheezing
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34353References
1. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, et al.
(2005) Cloning of a human parvovirus by molecular screening of respiratory
tract samples. Proc Natl Acad Sci U S A 102: 12891–12896.
2. Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, et al. (2007) Human
Bocavirus and Acute Wheezing in Children. Clin Infect Dis 44: 904–910.
3. Dakhama A, Hegele RG, Laflamme G, Israe ¨l-Assayag E, Cormier Y (1999)
Common respiratory viruses in lower airways of patients with acute
hypersensitivity pneumonitis. Am J Respir Crit Care Med 159: 1316–1322.
4. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, et al. (2006) The association of
newly identified respiratory viruses with lower respiratory tract infections in
Korean children, 2000–2005. Clin Infect Dis 43: 585–592.
5. Fan J, Henrickson KJ (1996) Rapid diagnosis of human parainfluenza virus type
1 infection by quantitative reverse transcription-PCREnzyme hybridization
assay. J Clin Microbiol 34: 1914–1917.
6. Bastien N, Brandt K, Dust K, Ward D, Li Y (2006) Human Bocavirus infection,
Canada. Emerg Infect Dis 12: 848–850.
7. Fry AM, Lu X, Chittaganpitch M, Peret T, Fischer J, et al. (2007) Human
bocavirus: a novel parvovirus epidemiologically associated with pneumonia
requiring hospitalization in Thailand. J Infect Dis 195: 1038–1045.
8. Gagliardi TB, Iwamoto MA, Paula FE, Proenca-Modena JL, Saranzo AM, et al.
(2009) Human bocavirus respiratory infections in children. Epidemiol Infect
137: 1032–1036.
9. Schildgen O, Muller A, Allander T, Mackay IM, Volz S, et al. (2008) Human
bocavirus: passenger or pathogen in acute respiratory tract infections? Clin
Microbiol Rev 21: 291–304.
10. Foulongne V, Rodiere M, Segondy M (2006) Human bocavirus in children.
Emerg Infect Dis 12: 862–863.
11. Yu D, Wei L, Zhengxiu L, Jian L, Lijia W, et al. (2010) Impact of bacterial
colonization on the severity and airway inflammation of children with virus
induced wheezing. Clin Microbiol Infect 6: 1399–1404.
12. Murray PR, Bron EJO, Pfaller MA, Tenover FC, Yolken RH (1980) Manual of
Clinical Microbiology, 6th edn. Washington DC: American Society of
Microbiology.
13. Murray PR, Washington JA (1975) Microscopic and bacteriologic analysis of
expectoratedsputum. Mayo Clin Proc 506: 339–344.
14. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, et al. (2012) Human
bocavirus-the first 5 years. Rev Med Virol 22: 46–64.
15. Kai Wanga, Wei Wanga, Huajie Yanb, Peijun Rena, Jing Zhanga, et al. (2010)
Correlation between bocavirus infection and humoral response, and co-infection
with other respiratory viruses in children with acute respiratory infection.
Journal of Clinical Virology 47: 148–155.
16. Liisa Lehtoranta, Maria Soderlund-Venermo, Johanna Nokso-Koivisto, Hanna
Toivola, Karin Blomgren, et al. (2012) Human bocavirus in the nasopharynx of
otitis-prone children. International Journal of Pediatric Otorhinolaryngology 76:
206–211.
17. Chung JY, Han TH, Kim JS, Kim SW, Park CG, et al. (2008) Th1 and Th2
cytokine levels in nasopharyngeal aspirates from children with human bocavirus
bronchiolitis. J Clin Virol 43: 223–225.
18. Van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, et al. (2001)
A newly discovered human pneunurvirus isolated from young children with
respiratory tract disease. Nat Med 7: 719–724.
19. Arden KE, McErlean P, Nissen MD, Sloots TP, Mackay IM (2006) Frequent
detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus
during acute respiratory tract infections. J Med Virol 78: 1232–1240.
20. Christensen A, Nordbø SA, Krokstad S, Rognlien AG, Døllner H (2010)
Human bocavirus in children: mono-detection, high viral load and viraemia are
associated with respiratory tract infection. Journal of Clinical Virology 49:
158–162.
21. Martin ET, Taylor J, Kuypers J, Magaret A, Wald A, et al. (2009) Detection of
bocavirus in saliva of children with and without respiratory illness. Journal of
Clinical Microbiology 47: 4131–4132.
22. Cheng WX, Jin Y, Duan ZJ, Xu ZQ, Qi HM, et al. (2008) Human bocavirus in
children hospitalized for acute gastroenteritis: a case-control study. Clinical
Infectious Diseases 47: 161–167.
23. von Linstow ML, Høgh M, Høgh B (2008) Clinical and epidemiologic
characteristics of human bocavirus in Danish infants: results from a prospective
birth cohort study. Pediatric Infectious Disease Journal 27: 897–902.
24. Martin ET, Fairchok MP, Kuypers J, Magaret A, Zerr DM, et al. (2010)
Frequent and prolonged shedding of bocavirus in young children attending
daycare. Journal of Infectious Diseases 201: 1625–1632.
25. Kesebir D, Vazquez M, Weibel C, Shapiro ED, Ferguson D, et al. (2006)
Human bocavirus infection in young children in the United States: molecular
epidemiological profile and clinical characteristics of a newly emerging
respiratory virus. Journal of Infectious Diseases 194: 1276–1282.
26. Maggi F, Andreoli E, Pifferi M, Meschi S, Rocchi J, et al. (2007) Human
bocavirus in Italian patients with respiratory diseases. Journal of Clinical
Virology 38: 321–325.
27. Brieu N, Guyon G, Rodie `reM, SegondyM, Foulongne V (2008) Human
bocavirus infection in children with respiratory tract disease. Pediatric Infectious
Disease Journal 27: 969–973.
28. Garcı ´a-Garcı ´a ML, Calvo C, Pozo F, Pe ´rez-Bren ˜a P, Quevedo S, et al. (2008)
Human bocavirus detection in nasopharyngeal aspirates of children without
clinical symptoms of respiratory infection. Pediatric Infectious Disease Journal
2008; 27: 358–360.
29. Longtin J, Bastien M, Gilca R, Leblanc E, de Serres G, et al. (2008) Human
bocavirus infections in hospitalized children and adults. Emerging Infectious
Diseases 14: 217–221.
30. Dijkman R, Koekkoek SM, Molenkamp R, Schildgen O, van der Hoek L (2009)
Human Bocavirus Can Be Cultured in Differentiated Human Airway Epithelial
Cells. J Virol 83: 7739–7748.
31. Collins PL, Hill MG, Johnson PR (1990) The two open reading frames of the
22K mRNA of human respiratory syncytial virus: sequence comparison of
antigenic subgroups A and B and expression in vitro. J Gen Virol 71:
3015–3020.
32. Karron RA, Froehlich L, Belshe RB, Belshe RB, Yolken RH (1994) Rapid
detection of parainfluenza virus type 3 RNA in respiratory specimens: use of
reverse transcription-PCR-enzyme immunoassay. J Clin Microbiol 32: 484–488.
33. Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, et al. (2006) Detection of
human bocavirus in Japanese children with lower respiratory tract infections.
J Clin Microbiol 44: 1132–1134.
34. Sloots TP, McErlean P, Speicher DJ, Arden KE, Nissen MD, et al. (2006)
Evidence of human coronavirus HKU1 and human bocavirus in Australian
children. J Clin Virol 35: 99–102.
35. Kahn JS, Kesebir D, Cotmore SF, D’Abramo A, Jr., Cosby C, et al. (2008)
Seroepidemiology of human bocavirus defined using recombinant virus-like
particles. J Infect Dis 198: 41–50.
36. Arnold JC, Singh KK, Spector SA, Sawyer MH (2006) Human bocavirus:
prevalence and clinical spectrum at a children’s hospital. Clin Infect Dis 43:
283–288.
37. Weissbrich BB, Neske FF, Schubert JJ, Tollmann F, Blath K, et al. (2006)
Frequent detection of bocavirus DNA in German children with respiratory tract
infections. BMC Infect Dis 6: 109.
38. Naghipour M, Cuevas LE, Bakhshinejad T, Dove W, Hart CA (2007) Human
bocavirus in Iranian children with acute respiratory infections. J Med Virol 79:
539–543.
39. Chung JY, Han TH, Kim CK, Kim SW (2006) Bocavirus infection in
hospitalized children, South Korea. Emerg Infect Dis 12: 1254–1256.
Human Bocavirus and Wheezing
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34353